Literature DB >> 19432769

Determination of sample sizes for demonstrating efficacy of radiation countermeasures.

Ralph L Kodell1, Shelly Y Lensing, Reid D Landes, K Sree Kumar, Martin Hauer-Jensen.   

Abstract

In response to the ever increasing threat of radiological and nuclear terrorism, active development of nontoxic new drugs and other countermeasures to protect against and/or mitigate adverse health effects of radiation is ongoing. Although the classical LD(50) study used for many decades as a first step in preclinical toxicity testing of new drugs has been largely replaced by experiments that use fewer animals, the need to evaluate the radioprotective efficacy of new drugs necessitates the conduct of traditional LD(50) comparative studies (FDA, 2002, Federal Register 67, 37988-37998). There is, however, no readily available method to determine the number of animals needed for establishing efficacy in these comparative potency studies. This article presents a sample-size formula based on Student's t for comparative potency testing. It is motivated by the U.S. Food and Drug Administration's (FDA's) requirements for robust efficacy data in the testing of response modifiers in total body irradiation experiments where human studies are not ethical or feasible. Monte Carlo simulation demonstrated the formula's performance for Student's t, Wald, and likelihood ratio tests in both logistic and probit models. Importantly, the results showed clear potential for justifying the use of substantially fewer animals than are customarily used in these studies. The present article may thus initiate a dialogue among researchers who use animals for radioprotection survival studies, institutional animal care and use committees, and drug regulatory bodies to reach a consensus on the number of animals needed to achieve statistically robust results for demonstrating efficacy of radioprotective drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432769      PMCID: PMC3036987          DOI: 10.1111/j.1541-0420.2009.01236.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

Review 1.  Major radiation exposure--what to expect and how to respond.

Authors:  Fred A Mettler; George L Voelz
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

2.  Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.

Authors:  Helen B Stone; John E Moulder; C Norman Coleman; K Kian Ang; Mitchell S Anscher; Mary Helen Barcellos-Hoff; William S Dynan; John R Fike; David J Grdina; Joel S Greenberger; Martin Hauer-Jensen; Richard P Hill; Richard N Kolesnick; Thomas J Macvittie; Cheryl Marks; William H McBride; Noelle Metting; Terry Pellmar; Mary Purucker; Mike E Robbins; Robert H Schiestl; Thomas M Seed; Joseph E Tomaszewski; Elizabeth L Travis; Paul E Wallner; Mary Wolpert; Daniel Zaharevitz
Journal:  Radiat Res       Date:  2004-12       Impact factor: 2.841

Review 3.  Priority list of research areas for radiological nuclear threat countermeasures.

Authors:  Terry C Pellmar; Sara Rockwell
Journal:  Radiat Res       Date:  2005-01       Impact factor: 2.841

4.  A simple method of sample size calculation for linear and logistic regression.

Authors:  F Y Hsieh; D A Bloch; M D Larsen
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  An up-and-down procedure for acute toxicity testing.

Authors:  R D Bruce
Journal:  Fundam Appl Toxicol       Date:  1985-02

6.  Radioprotection by N-palmitoylated nonapeptide of human interleukin-1beta.

Authors:  Vijay K Singh; Venkataraman Srinivasan; Thomas M Seed; William E Jackson; Venita E Miner; K Sree Kumar
Journal:  Peptides       Date:  2005-03       Impact factor: 3.750

7.  Planning a quantal assay of potency.

Authors:  B W Brown
Journal:  Biometrics       Date:  1966-06       Impact factor: 2.571

8.  New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2002-05-31

9.  Acute oral toxicity.

Authors:  E Walum
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

10.  Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group.

Authors:  Jamie K Waselenko; Thomas J MacVittie; William F Blakely; Nicki Pesik; Albert L Wiley; William E Dickerson; Horace Tsu; Dennis L Confer; C Norman Coleman; Thomas Seed; Patrick Lowry; James O Armitage; Nicholas Dainiak
Journal:  Ann Intern Med       Date:  2004-06-15       Impact factor: 25.391

View more
  9 in total

1.  Statistical analysis of survival data from radiation countermeasure experiments.

Authors:  Reid D Landes; Shelly Y Lensing; Ralph L Kodell; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2012-03-08       Impact factor: 2.841

2.  NZO/HlLtJ as a novel model for the studies on the role of metabolic syndrome in acute radiation toxicity.

Authors:  Laura E Ewing; Isabelle R Miousse; Rupak Pathak; Charles M Skinner; Stanley Kosanke; Marjan Boerma; Martin Hauer-Jensen; Igor Koturbash
Journal:  Int J Radiat Biol       Date:  2019-01-14       Impact factor: 2.694

3.  Pentoxifylline enhances the radioprotective properties of γ-tocotrienol: differential effects on the hematopoietic, gastrointestinal and vascular systems.

Authors:  Maaike Berbée; Qiang Fu; Sarita Garg; Shilpa Kulkarni; K Sree Kumar; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2010-12-28       Impact factor: 2.841

4.  Preclinical evaluation of Som230 as a radiation mitigator in a mouse model: postexposure time window and mechanisms of action.

Authors:  Qiang Fu; Maaike Berbée; Wenze Wang; Marjan Boerma; Junru Wang; Herbert A Schmid; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2011-04-29       Impact factor: 2.841

5.  Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs.

Authors:  Reid D Landes; Shelly Y Lensing; Martin Hauer-Jensen
Journal:  J Biopharm Stat       Date:  2018-10-23       Impact factor: 1.051

6.  The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival after total-body irradiation by inhibiting exocrine pancreatic secretion.

Authors:  Qiang Fu; Maaike Berbée; Marjan Boerma; Junru Wang; Herbert A Schmid; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2009-06       Impact factor: 2.841

7.  Practical advice on calculating confidence intervals for radioprotection effects and reducing animal numbers in radiation countermeasure experiments.

Authors:  Reid D Landes; Shelly Y Lensing; Ralph L Kodell; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2013-10-28       Impact factor: 2.841

8.  RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.

Authors:  Kimberly J Jurgensen; William K J Skinner; Bryan Oronsky; Nacer D Abrouk; Andrew E Graff; Reid D Landes; William E Culp; Thomas A Summers; Lynnette H Cary
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

9.  Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity.

Authors:  Hartmut Geiger; Snehalata A Pawar; Edward J Kerschen; Kalpana J Nattamai; Irene Hernandez; Hai Po H Liang; Jose Á Fernández; Jose A Cancelas; Marnie A Ryan; Olga Kustikova; Axel Schambach; Qiang Fu; Junru Wang; Louis M Fink; Karl-Uwe Petersen; Daohong Zhou; John H Griffin; Christopher Baum; Hartmut Weiler; Martin Hauer-Jensen
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.